LT3098239T - Į egfr nukreipiamas dvigrandis rnr vektorius, skirtas sisteminiam vėžio gydymui - Google Patents
Į egfr nukreipiamas dvigrandis rnr vektorius, skirtas sisteminiam vėžio gydymuiInfo
- Publication number
- LT3098239T LT3098239T LTEP16177258.7T LT16177258T LT3098239T LT 3098239 T LT3098239 T LT 3098239T LT 16177258 T LT16177258 T LT 16177258T LT 3098239 T LT3098239 T LT 3098239T
- Authority
- LT
- Lithuania
- Prior art keywords
- cancer treatment
- rna vector
- egfr targeted
- targeted double
- systemic cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 title 1
- 230000009885 systemic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Information Transfer Between Computers (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13969808P | 2008-12-22 | 2008-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3098239T true LT3098239T (lt) | 2020-02-10 |
Family
ID=42104511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP16177258.7T LT3098239T (lt) | 2008-12-22 | 2009-12-22 | Į egfr nukreipiamas dvigrandis rnr vektorius, skirtas sisteminiam vėžio gydymui |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9006406B2 (lt) |
| EP (3) | EP3705493A1 (lt) |
| JP (1) | JP2012513210A (lt) |
| CN (1) | CN102325794A (lt) |
| AU (1) | AU2009332522A1 (lt) |
| BR (1) | BRPI0922985A2 (lt) |
| CA (1) | CA2748125A1 (lt) |
| CY (1) | CY1123371T1 (lt) |
| DK (2) | DK2379597T3 (lt) |
| ES (2) | ES2602753T3 (lt) |
| HR (1) | HRP20192317T1 (lt) |
| HU (1) | HUE047759T2 (lt) |
| IL (1) | IL213739A0 (lt) |
| LT (1) | LT3098239T (lt) |
| MX (1) | MX2011006720A (lt) |
| PL (1) | PL3098239T3 (lt) |
| PT (1) | PT3098239T (lt) |
| SI (1) | SI3098239T1 (lt) |
| SM (1) | SMT202000038T1 (lt) |
| WO (1) | WO2010073247A2 (lt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104394846B (zh) * | 2012-05-03 | 2018-10-19 | 爱尔兰詹森科学公司 | 用于治疗上呼吸道感染的聚肌苷酸-聚胞苷酸（聚(i:c)）配制品 |
| JP6103832B2 (ja) | 2012-06-25 | 2017-03-29 | Hoya株式会社 | Ｅｇｆｒ結合性ペプチド |
| US9431064B2 (en) * | 2012-11-02 | 2016-08-30 | Taiwan Semiconductor Manufacturing Company, Ltd. | Memory circuit and cache circuit configuration |
| US10796320B2 (en) * | 2013-12-23 | 2020-10-06 | Mastercard International Incorporated | Systems and methods for passively determining a ratio of purchasers and prospective purchasers in a merchant location |
| CN116966310A (zh) * | 2014-05-14 | 2023-10-31 | 塔歌牧恩治疗公司 | 改善的聚乙烯亚胺聚乙二醇载体 |
| EP3274840A4 (en) * | 2015-03-27 | 2018-12-26 | Intel Corporation | Dynamic cache allocation |
| WO2017085228A1 (en) * | 2015-11-17 | 2017-05-26 | Bioncotech Therapeutics, S.L | Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine |
| GB201601868D0 (en) * | 2016-02-02 | 2016-03-16 | Lytix Biopharma As | Methods |
| CN105669964B (zh) * | 2016-03-04 | 2017-11-21 | 博瑞生物医药（苏州）股份有限公司 | 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用 |
| CN109790225B (zh) * | 2016-09-04 | 2022-09-09 | 塔尔格免疫治疗有限公司 | 用于靶向dsRNA的嵌合蛋白 |
| CA3063805C (en) * | 2017-05-17 | 2024-01-09 | Bioncotech Therapeutics Sl | Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine |
| JP2020535171A (ja) * | 2017-09-27 | 2020-12-03 | ターグイミューン セラピューティクス アーゲー | 去勢抵抗性前立腺癌 |
| CN113543809A (zh) * | 2019-04-03 | 2021-10-22 | 塔尔格免疫治疗有限公司 | 用于治疗癌症的免疫疗法 |
| WO2020263770A1 (en) * | 2019-06-24 | 2020-12-30 | North Carolina State University | Nucleic acid compositions including a polyalkyleneimine-alkoxylene polymer and methods of making and using the same |
| WO2020263776A1 (en) * | 2019-06-24 | 2020-12-30 | North Carolina State University | Nucleic acid compositions including a polyalkyleneimine-alkoxylene polymer and methods of making and using the same |
| US10915418B1 (en) * | 2019-08-29 | 2021-02-09 | Snowflake Inc. | Automated query retry in a database environment |
| JP2025537216A (ja) | 2022-11-07 | 2025-11-14 | ターグイミューン セラピューティクス アクチエンゲゼルシャフト | 核酸とポリエチレンイミンおよびポリエチレングリコールを含む標的化コンジュゲートとのポリプレックス |
| WO2025238236A1 (en) | 2024-05-16 | 2025-11-20 | Targimmune Therapeutics Ag | Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927792B2 (en) | 2002-11-18 | 2011-04-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Targeted double stranded RNA mediated cell killing |
| WO2006054129A1 (en) * | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Improved treatment of cancer by double-stranded rna |
| US7937291B2 (en) * | 2009-04-22 | 2011-05-03 | Visa U.S.A. Inc. | Providing an announcement about transactions of a target merchant to a consumer |
-
2009
- 2009-12-22 BR BRPI0922985A patent/BRPI0922985A2/pt not_active IP Right Cessation
- 2009-12-22 DK DK09806144.3T patent/DK2379597T3/en active
- 2009-12-22 CA CA2748125A patent/CA2748125A1/en not_active Abandoned
- 2009-12-22 DK DK16177258.7T patent/DK3098239T3/da active
- 2009-12-22 LT LTEP16177258.7T patent/LT3098239T/lt unknown
- 2009-12-22 EP EP19204643.1A patent/EP3705493A1/en active Pending
- 2009-12-22 HU HUE16177258A patent/HUE047759T2/hu unknown
- 2009-12-22 EP EP16177258.7A patent/EP3098239B1/en active Active
- 2009-12-22 MX MX2011006720A patent/MX2011006720A/es not_active Application Discontinuation
- 2009-12-22 SI SI200932023T patent/SI3098239T1/sl unknown
- 2009-12-22 PL PL16177258T patent/PL3098239T3/pl unknown
- 2009-12-22 SM SM20200038T patent/SMT202000038T1/it unknown
- 2009-12-22 ES ES09806144.3T patent/ES2602753T3/es active Active
- 2009-12-22 ES ES16177258T patent/ES2764396T3/es active Active
- 2009-12-22 EP EP09806144.3A patent/EP2379597B8/en active Active
- 2009-12-22 JP JP2011542970A patent/JP2012513210A/ja not_active Withdrawn
- 2009-12-22 US US13/141,345 patent/US9006406B2/en active Active
- 2009-12-22 AU AU2009332522A patent/AU2009332522A1/en not_active Abandoned
- 2009-12-22 PT PT161772587T patent/PT3098239T/pt unknown
- 2009-12-22 WO PCT/IL2009/001210 patent/WO2010073247A2/en not_active Ceased
- 2009-12-22 CN CN2009801572556A patent/CN102325794A/zh active Pending
-
2011
- 2011-06-23 IL IL213739A patent/IL213739A0/en unknown
- 2011-09-22 US US13/239,784 patent/US20120330998A1/en not_active Abandoned
-
2019
- 2019-12-20 CY CY20191101340T patent/CY1123371T1/el unknown
- 2019-12-23 HR HRP20192317TT patent/HRP20192317T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT3098239T (pt) | 2020-01-15 |
| CA2748125A1 (en) | 2010-07-01 |
| IL213739A0 (en) | 2011-07-31 |
| EP2379597B1 (en) | 2016-08-10 |
| BRPI0922985A2 (pt) | 2016-10-04 |
| ES2602753T3 (es) | 2017-02-22 |
| EP3098239B1 (en) | 2019-10-23 |
| JP2012513210A (ja) | 2012-06-14 |
| US20120021006A1 (en) | 2012-01-26 |
| CN102325794A (zh) | 2012-01-18 |
| SMT202000038T1 (it) | 2020-03-13 |
| PL3098239T3 (pl) | 2020-04-30 |
| US20120330998A1 (en) | 2012-12-27 |
| HUE047759T2 (hu) | 2020-05-28 |
| SI3098239T1 (sl) | 2020-03-31 |
| CY1123371T1 (el) | 2021-10-29 |
| WO2010073247A2 (en) | 2010-07-01 |
| DK2379597T3 (en) | 2016-12-05 |
| MX2011006720A (es) | 2011-10-06 |
| WO2010073247A3 (en) | 2010-08-19 |
| EP2379597A2 (en) | 2011-10-26 |
| DK3098239T3 (da) | 2020-01-20 |
| ES2764396T3 (es) | 2020-06-03 |
| EP2379597B8 (en) | 2016-11-30 |
| AU2009332522A1 (en) | 2011-08-11 |
| US9006406B2 (en) | 2015-04-14 |
| EP3705493A1 (en) | 2020-09-09 |
| HRP20192317T1 (hr) | 2020-03-20 |
| EP3098239A1 (en) | 2016-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3098239T (lt) | Į egfr nukreipiamas dvigrandis rnr vektorius, skirtas sisteminiam vėžio gydymui | |
| LTC2076540I2 (lt) | Nauji anti-cd38 antikūnai, skirti vėžio gydymui | |
| BRPI0810206A2 (pt) | Método de tratar câncer | |
| EP2303337A4 (en) | SMALL MOLECULAR LIGANDEN MEDICINAL CONJUGATES FOR TARGETED CANCER THERAPY | |
| NO2021006I1 (no) | Quofenix, delafloksacin | |
| BRPI0918122A8 (pt) | molécula de diabody, diabody, e mólecula dart | |
| BRPI0923341A2 (pt) | oligonucleotideos imunoestimuladores | |
| LT3287525T (lt) | Rnr preparatai, apimantys išgrynintą modifikuotą rnr, skirti ląstelių reprogramavimui | |
| DK2121139T3 (da) | Formulations for cancer treatment | |
| LT3026064T (lt) | Antikūnai, skirti vėžio gydymui, ekspresuojantys klaudiną 6 | |
| HUE037645T2 (hu) | Rák kezelésére alkalmas 2.(2,4,5-helyettesített-anilino)pirimidin származékok mint EGFR modulátorok | |
| FR2929502B1 (fr) | Implant nucleique. | |
| BRPI0921122A2 (pt) | sistema de terapia de próstata. | |
| BRPI0921422A2 (pt) | sistema de terapia de próstata. | |
| BRPI0923912A2 (pt) | aparelho de cateter. | |
| BRPI0811755A2 (pt) | Amplificação específica de senquência de dna específicas de tumor. | |
| BRPI0922208A2 (pt) | método de mineração de minerio. | |
| BRPI0816150A2 (pt) | genes relacionados com câncer, cdca5, eph47, stk31 e w-dhd1. | |
| DK2219683T3 (da) | Målrettet radioterapi | |
| BR112012002797A2 (pt) | tratamento de câncer de próstata | |
| HUE039385T2 (hu) | ABCB5 rákterápiás célzása | |
| EP2283862A4 (en) | ANTITUMOR AGENT | |
| BRPI0922884A2 (pt) | compostos para tratamento de câncer | |
| BRPI0813789A2 (pt) | Potenciação de quimioterapia contra câncer | |
| DK2147122T3 (da) | Enzymatisk kræftbehandling |